Aprea Therapeutics Inc (APRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.91M
Last updated: Nov 17, 2026 at 11:02 AM ET
Aprea Therapeutics Inc (APRE) Stock Forecast
Analysts expect Aprea Therapeutics (APRE) to earn -$0.39 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.44.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 25.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.39
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.44
- EPS consensus
- Next report
- Mar 15, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.39 | -$0.40 to -$0.38 | 3 |
| Dec 31, 2027 | -$0.44 | -$0.53 to -$0.35 | 3 |
Quarterly Estimates
The EPS consensus falls from -$0.09 for the quarter ending Dec 31, 2026 to -$0.13 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.11 to -$0.05 | 6 |
| Mar 31, 2027 | -$0.13 | -$0.13 to -$0.13 | 1 |
Estimate Revisions
No EPS estimate for the 3 periods below was revised in the last 30 days.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.83.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.39 | -$0.36 | -$0.34 | -$0.34 | -$0.83 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.44 | -$0.40 | -$0.34 | -$0.34 | -$0.83 | N/A |
| Quarter ending Mar 31, 2027 | -$0.13 | -$0.11 | -$0.08 | -$0.08 | -$0.25 | N/A |
Frequently Asked Questions About APRE
What is the APRE stock forecast?
Consensus analyst estimates put Aprea Therapeutics's EPS at -$0.39 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Buy.
How do analysts rate APRE stock?
Of 4 analysts covering Aprea Therapeutics, 1 rates it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from APRE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.39, with estimates from -$0.40 to -$0.38 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.44, with estimates from -$0.53 to -$0.35 from 3 analysts.
How many analysts cover APRE?
4 analysts rate Aprea Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
APRE pages: Overview, Earnings, Forecast, Financials, Competitors